NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T
Cell. 2018 175 (7): 1744-1755.e15

PMID: 30503208 · PMCID: PMC6354585 · DOI:10.1016/j.cell.2018.10.028

Tumor-infiltrating CD8 T cells were found to frequently express the inhibitory receptor NKG2A, particularly in immune-reactive environments and after therapeutic cancer vaccination. High-dimensional cluster analysis demonstrated that NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. To examine whether NKG2A represented an adaptive resistance mechanism to cancer vaccination, we blocked the receptor with an antibody and knocked out its ligand Qa-1, the conserved ortholog of HLA-E, in four mouse tumor models. The impact of therapeutic vaccines was greatly potentiated by disruption of the NKG2A/Qa-1 axis even in a PD-1 refractory mouse model. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. These findings indicate that NKG2A-blocking antibodies might improve clinical responses to therapeutic cancer vaccines.

Copyright © 2018 Elsevier Inc. All rights reserved.

MeSH Terms (15)

Animals Antibodies, Neoplasm Antigens, CD Cancer Vaccines CD8-Positive T-Lymphocytes Cell Line, Tumor Histocompatibility Antigens Class I Humans Immunity, Cellular Integrin alpha Chains Mice Neoplasm Proteins Neoplasms, Experimental NK Cell Lectin-Like Receptor Subfamily C Vaccination

Connections (2)

This publication is referenced by other Labnodes entities: